Akums Drugs & Pharmaceuticals Ltd, established in 2004 as India’s leading pharmaceutical CDMO offering comprehensive product development and manufacturing services across formulations, reported lower profitability for Q2FY26.
Financial Highlights:
- Revenues declined 1.45% year-on-year to ₹1,018 crore from ₹1,033 crore, with CDMO up 0.7% to ₹804 crore but API/international formulations down.
- Total expenses rose 2.61% to ₹984 crore from ₹959 crore.
- Consolidated net profit fell 35.82% to ₹43 crore from ₹67 crore, with EBITDA at ₹94 crore (9.3% margin).
- Earnings per share dropped 37.44% to ₹2.59 from ₹4.14.
Challenges from API price weakness and flat volumes impacted performance despite domestic formulations growth of 5.3%.
Outlook:
Akums Drugs & Pharmaceuticals Ltd focuses on branded exports (Dapagliflozin to Switzerland), EU-GMP expansion, and domestic growth to improve margins and shareholder value.
Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.